Deal watch: GSK invests in targeting microRNA for the treatment of hepatitis C.
D000818:Animals; D000998:Antiviral Agents / Q000191:economics / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000191:economics; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D006526:Hepatitis C / Q000628:therapy* / Q000821:virology; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; C531907:MIRN122 microRNA, human; D035683:MicroRNAs